Approved for us

U.S. Patent and Trademark Office

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a critic-tion of information uniformation.

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
( Not for submission under 37 CFR 1.99)

	Application Number		10830224	
	Filing Date		2004-04-23	
	First Named Inventor	Richi	ard Banks	
	Art Unit		2173	
	Examiner Name	John	W. Cabeca	
	Attorney Docket Number		003797.01271	

			Remove			
		Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear			
	1	6636250		2003-10-21	Gasser	
If you wis	h to a	dd additional U.S. Paten	t citatio	n information pl	ease click the Add button.	Add
			U.S.P	ATENT APPLI	CATION PUBLICATIONS	Remove
Examiner Initial*			Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear			
	1	20050027757		2005-02-03	Kiessig, et al.	
	2	20050080807		2005-04-14	Belinson, et al.	
	3	20040167942		2004-08-26	Oshinsky, et al.	
	4	20010047368		2001-11-29	Oshinsky, et al.	
	5	20030227487		2003-12-11	Hugh	

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10830224		
Filing Date		2004-04-23		
First Named Inventor	Richard Banks			
Art Unit		2173		
Examiner Name	John W. Cabeca			
Attorney Docket Number		002707 01271		

	6	20040044696	20	2004-03-04		Frost					
	7	20030154185	20	03-08-14		Suzukı, et al.					
If you wis	h to a	dd additional U.S. Publi	shed Applic	ation cita	tior	information p	olease click the Add	butto	n. Add		
			FO	REIGN P	ΑT	ENT DOCUM	ENTS		Remove	•	
Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Country Code <sup>2</sup> i					levant s or Relevant	TS		
	1										
If you wis	h to a	dd additional Foreign P	atent Docun	nent citati	ion	information pl	ease click the Add	buttor	Add		
	NON-PATENT LITERATURE DOCUMENTS Remove										
Examiner Initials*	Examiner Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item Initials* No (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.						Τs				
	1										

EXAMINER SIGNATURE

Examiner Signature Date Considered

If you wish to add additional non-patent literature document citation information please click the Add button Add

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

See Kinc Code of USPTO Potent Documents at www.LSPTO.COV or MPEP 901.04. I failer of oftice that asseed the document, by the how letter own WIPPO Standard ST3.) "For Just planese petral for counters, the included on the year of the register of the Empior or many precise of the errain under precise of the errain under WIPPO Standard ST3.16 if possible. "Applicant is to place a check many here of Empirical Institute or Standard ST3.16 if possible." Applicant is to place a check many here of Empirish Institutes the Institute on Standard ST3.16 if possible. "Applicant is to place a check many here if

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10830224		
Filing Date		2004-04-23		
First Named Inventor	Richard Banks			
Art Unit		2173		
Examiner Name	John W. Cabeca			
Attorney Docket Number		003797.01271		

#### CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 197(eVI).

#### ΩR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1,59(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1,397(c) and the contraction of the contraction of

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- 7 None

#### SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Jordan N. Bodner/	Date (YYYY-MM-DD)	2006-06-22
Name/Print	Jordan N. Bodner	Registration Number	42 338

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life and by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C.12 GA 37 CFR.

1.14. This collection is estimated to take I hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, u.S. Operatment of Commence, P. O. Box 1430, Alexandriu, V.S. 2213.1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandriu, V.S. 2213.1450.

### Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that (1) the general authority for the collection of this information is \$3 U.S.C. 2(b)(2); (2) famishing of the information solicided is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan Kollie is to process and/or examine your submission related to a patient application or patient. If you do not furnish the requested process and/or examine your submission related to a patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested to the patient process and/or examine your submission, which may related that the patient process and/or examine your submission, which may

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
  - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiation.
  - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record partains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
  - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, pursuant to 5 U.S.C. 552a(m.).
  - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
    may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
    to the Patent Cooperation Treaty.
  - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designe, cuting an inspection of records concluded by GSAs a part of that apency's responsibility to recommend improvements in records management practices and programs, under suthority of 4d U.S.C. 2004 and 2006. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 12(b) or issuance of a patient pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR.114, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application port to public insepticines or an issuand patient.
  - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.